BioSpace News Archive

Eli Lilly and Company announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo® demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal malignancies.

First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group)

The combination showed preliminary antitumor activity in patients with unresectable or metastatic melanoma refractory or resistant to PD-1/L1 inhibitors and platinum-resistant ovarian cancer in an ongoing Phase 1b clinical trial, with a generally well-tolerated safety profile.

In response to growing business demand, Aran Biomedical Teoranta, a leading biomaterials contract manufacturer of proprietary medical devices, announced the creation of 150 new jobs over 3 years.

New patient-reported outcomes data from PATHFINDER trial show AYVAKIT significantly reduced disease symptoms and improved quality of life

Taiho Oncology, Inc. announced efficacy and safety results from the Phase 2 FOENIX-CCA2 trial, a single-arm multicenter Phase 2 study evaluating futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements including gene fusions who have failed at least one line of therapy.

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced the presentation of new translational data from Checkmate’s Phase 1b trial of vidutolimod in combination with pembrolizumab in patients with advanced anti-PD-1 refractory melanoma.

Antengene Corporation Limited announced that the first patient has been dosed in a phase II trial in China of ATG-008, a second-generation mTORC1/2 inhibitor, for the treatment of advanced solid tumors harboring NFE2L2, STK11, RICTOR or other specific genetic alterations.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced positive interim results from the ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational RNAi therapeutic targeting liver-expressed angiotensinogen for the treatment of hypertension.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.